GlassScriptPhysician profile
Theodore John Rogers
NPI 1699111781
$6,719.64
in general payments reported to CMS, 2019-2025
35 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $117 · 2021: $1,199 · 2022: $1,787 · 2023: $855 · 2024: $1,346 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,081.70 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $698.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $355.43 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $305.62 | 2019-2025 | Evenity, Prolia, Prolia |
| Novartis Pharmaceuticals Corporation | $302.32 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.27 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $164.00 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $142.26 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $123.10 | 2022 | |
| Merck Sharp & Dohme LLC | $113.19 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $106.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $105.85 | 2021-2025 | Farxiga, Breztri |
| Organon LLC | $76.26 | 2021-2024 | Nexplanon |
| Sunovion Pharmaceuticals INC. | $75.77 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.98 | 2025 | Caplyta |
| Astellas Pharma US INC | $62.79 | 2021-2024 | Veozah |
| Pfizer INC. | $59.81 | 2020-2025 | |
| Amarin Pharma, INC. | $51.61 | 2020-2022 | |
| Exact Sciences Corporation | $38.14 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $36.73 | 2023-2024 | Gemtesa |
| Dexcom, INC. | $32.88 | 2022-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $32.43 | 2021 | |
| Allergan, INC. | $32.03 | 2020 | |
| Abbott Laboratories | $28.70 | 2021 | |
| Exeltis, USA INC. | $27.40 | 2020-2022 | |
| Medtronic, INC. | $22.00 | 2025 | Inceptiv |
| Optumhealth Care Solutions, LLC | $21.85 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Lundbeck LLC | $16.28 | 2025 | Rexulti |
| Viatris Specialty LLC | $14.38 | 2025 | Yupelri |
| Supernus Pharmaceuticals, INC. | $14.29 | 2022 | |
| Sanofi Pasteur INC. | $14.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.75 | 2021 | |
| Mylan Specialty L.P. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.